German Cancer Research Center

Study identifies PRDX6 enzyme crucial for selenoprotein production, offering potential to inhibit GPX4 and target neuroblastoma in children.

600+ participants from 31 countries attended the PMNET Forum, a leading Precision Medicine event in the Nordic region, focusing on improving patient care through collaboration and innovation. Key agreements were signed, including the creation of a Centre of Excellence for Precision Medicine in Pediatric Care in Latvia. The forum also featured a health hackathon and a position paper by the American Chamber of Commerce in Latvia on the economic value of health innovation.

Carina Seidl will explore axolotl tail regeneration, tracking neuron types and their connectivity using light sheet imaging. She will analyze swimming ability and behavioral responses to assess neural network restoration, aiming to understand the accuracy required for functional recovery, potentially aiding spinal injury treatments.

Germany IVD raw materials market valued at USD 989.1 million in 2024, projected to reach USD 2,658.9 million by 2033, growing at a CAGR of 11.7%. Driven by chronic disease prevalence, government healthcare investments, and diagnostic tech advancements. High regulatory standards and compliance costs are restraining factors. Personalized medicine adoption offers significant market opportunities.

Inavolisib (GDC-0077) showed a disease control rate (DCR) of 60% at 8 weeks and 32% at 16 weeks in patients with PIK3CA-mutated advanced solid tumors, with a favorable safety profile. The median progression-free survival was 3.52 months, and the 12-month overall survival rate was 51%. The most common adverse effects were hyperglycemia, diarrhea, fatigue, and constipation, mostly grade 1 or 2.

CRAFT interim analysis shows inavolisib (GDC-0077) promising in disease control for rare tumors, with 36% disease control rate in PIK3CA-mutated tumors. Presented at ESMO 2024, ongoing CRAFT trial aims to confirm efficacy and safety across various disease states.